KEYNOTE-240

NCT02702401 📎

Regimen

Experimental
pembrolizumab + BSC
Control
placebo + BSC

Population

Advanced hepatocellular carcinoma previously treated with sorafenib

Key finding

mOS 13.9 vs 10.6 mo (HR 0.781, 95% CI 0.611-0.998, p=0.0238) — **did NOT meet prespecified threshold p≤0.0174**; mPFS 3.0 vs 2.8 mo (HR 0.718, p=0.0022 vs threshold p≤0.002 — also missed); despite numerical benefit, trial technically negative; global cohort including Western patients

Source: PMID 31790344

Timeline

    Guideline citations

    • NCCN HCC (p.18)